Core Points - Alexander's, Inc. will file its quarterly report on Form 10Q for the quarter ended March 31, 2025, with the U.S. Securities and Exchange Commission and will issue its first quarter earnings release on May 5, 2025, before the market opens [1] - Vornado Realty Trust, which manages Alexander's operations, will host a quarterly earnings conference call and audio webcast on May 6, 2025, at 10:00 a.m. Eastern Time [2] - The conference call can be accessed via a domestic and international dialing option, and a live webcast will be available on Vornado's website [3] Company Overview - Alexander's, Inc. is a real estate investment trust (REIT) that owns five properties in New York City [3]

Group 1 - The recent heavy sell-off in the market has created opportunities in high-yield REITs, attracting investors seeking higher returns as a hedge against volatility [1] - There is a cautionary note that the yield advertised may not reflect the actual yield received, as companies have the ability to cut dividends [1]

Group 1 - NCR Atleos Corporation (NATL) has seen a 9% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - BGC Group, Inc. (BGC) has experienced a 9.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Naspers Limited (NPSNY) has seen a 14.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Alexander's, Inc. (ALX) has experienced a 15% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Veeva Systems Inc. (VEEV) has seen a 4.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2]

Group 1 - Alexander's (ALX) has gained about 5.3% year-to-date, outperforming the average gain of 2.4% for Finance stocks [4] - The Zacks Rank for Alexander's is 2 (Buy), indicating a positive earnings outlook with a 15% increase in the consensus estimate for full-year earnings over the past 90 days [3] - Alexander's belongs to the REIT and Equity Trust - Other industry, which has seen a year-to-date gain of 4.3%, indicating that ALX is performing better than its peers in this specific group [5] Group 2 - Banco Bilbao (BBVA) has significantly outperformed the sector with a year-to-date return of 41.2% and has a Zacks Rank of 1 (Strong Buy) [4][5] - The Banks - Foreign industry, to which Banco Bilbao belongs, is ranked 29 and has moved up by 10.2% this year [6] - Investors interested in Finance stocks should closely monitor both Alexander's and Banco Bilbao for their solid performance [6]

Investors might want to bet on Alexander's (ALX) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The ...

Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 28:                     Alexander's, Inc. (ALX) : This real estate investment trust witnessed the Zacks Consensus Estimate for its current year earnings increasing 15% the last 60 days.This Zacks Rank #1 company has a dividend yield of 8.5%, compared with the industry average of 4.9%.Hanmi Financial Corporation (HAFC) : This holding company for Hanmi Bank has witnessed the Zacks Consensus Estimate fo ...

Group 1: Market Overview - Optimistic rhetoric from the Federal Reserve has calmed markets amid ongoing tariff concerns, suggesting a potential rebound in stocks [1] - Stocks on the Zacks Rank 1 (Strong Buy) list are highlighted as suitable candidates for investment, particularly those offering generous dividends [1] Group 2: Cal-Maine Foods - Cal-Maine Foods (CALM), the largest producer of fresh-shell eggs in the U.S., has seen its stock pull back 20% from a 52-week high of $116, presenting a buying opportunity [2] - The company is expected to benefit from high egg prices due to bird flu outbreaks and seasonal demand, with current prices near $6 per dozen [3] - Cal-Maine's EPS is projected to increase over 170% this year to $15.59, trading at 5.9X forward earnings, while offering a dividend yield of 6.39% [3] Group 3: Alexander's - Alexander's (ALX), a developer of residential properties in New York City, is trading at $212, rebounding from a low of $184 but still 19% below its peak of over $250 [4] - EPS estimates for fiscal years 2025 and 2026 have risen over 15% and 26% respectively, with ALX trading at 18.6X forward earnings and offering an 8.41% annual dividend [5] Group 4: First Merchants - First Merchants (FRME) operates over 110 banking locations in the Midwest and is projected to see annual sales rise over 4% in FY25 and FY26, nearing $700 million [7] - The company's earnings are expected to increase 11% in FY25 and another 8% next year, with an EPS forecast of $4.16, while offering a 3.39% annual dividend and trading at 10.7X forward earnings [8] Group 5: Conclusion - The trend of positive earnings estimate revisions for these highly ranked stocks, combined with attractive dividends, is reassuring for investors as the broader market stabilizes [10]

Core Insights - Three stocks with strong income characteristics and buy rank are highlighted for investors to consider on March 25th Group 1: Alexander's, Inc. (ALX) - This real estate investment trust has seen a 15% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - The company has a dividend yield of 8.5%, significantly higher than the industry average of 4.9% [1] Group 2: Hanmi Financial Corporation (HAFC) - This holding company for Hanmi Bank has experienced a 6.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - The company offers a dividend yield of 4.8%, compared to the industry average of 3.1% [2] Group 3: Horizon Bancorp, Inc. (HBNC) - This holding company for Horizon Bank has seen a 6.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] Group 4: Additional Insights - Another Zacks Rank 1 company has a dividend yield of 4.2%, which is above the industry average of 2.9% [3]

Company Performance - Alexander's (ALX) has gained approximately 6.2% year-to-date, outperforming the average gain of 1% in the Finance sector [4] - The Zacks Consensus Estimate for ALX's full-year earnings has increased by 15% over the past quarter, indicating a positive earnings outlook [3] Industry Context - Alexander's is part of the REIT and Equity Trust - Other industry, which consists of 98 companies and is currently ranked 131 in the Zacks Industry Rank [5] - The average gain for the REIT and Equity Trust - Other industry is 3.3% year-to-date, showing that Alexander's is performing better than its industry peers [5] - Banco Bilbao (BBVA), another stock in the Finance sector, has significantly outperformed with a year-to-date increase of 47.5% [4]

Core Insights - ALX Oncology presented positive data from the ASPEN-06 Phase 2 trial, showing that evorpacept provides strong responses and durable clinical benefits in HER2-positive gastric cancer patients [1] - The company announced a focused development plan for evorpacept, including clinical trials in breast and colorectal cancers, and a new EGFR-targeted antibody-drug conjugate [1][4] - ALX Oncology's strategic prioritization and resource optimization efforts are expected to extend its cash runway into Q4 2026 [1][4] Clinical Developments - Updated results from the ASPEN-06 trial indicated a confirmed objective response rate (cORR) of 48.9% and a median duration of response (mDOR) of 15.7 months for evorpacept compared to 24.5% cORR and 9.1 months mDOR in the control group [4] - At the SABCS 2024, evorpacept in combination with zanidatamab showed a cORR of 55.6% and a median progression-free survival (mPFS) of 7.4 months in HER2-positive metastatic breast cancer patients [4] Financial Performance - As of December 31, 2024, ALX Oncology reported cash, cash equivalents, and investments totaling $131.3 million, sufficient to fund operations into Q4 2026 [6][12] - R&D expenses for Q4 2024 were $23.5 million, a decrease from $41.8 million in the prior year, primarily due to reduced clinical and development costs [6][11] - The GAAP net loss for Q4 2024 was $29.2 million, down from $45.5 million in Q4 2023, attributed to lower R&D expenses [8][11] Leadership Changes - ALX Oncology announced key additions to its leadership team, including Dr. Allison Dillon as Chief Business Officer and Dr. Alan Sandler as Chief Medical Officer [2][7] - The company is streamlining its organization, resulting in approximately a 30% workforce reduction primarily in preclinical research [4]